Recently it has been realized that empiric therapeutic dosing is suboptimal due to inter-patient variability with regard to response, receptor concentration etc.
Hence there is a clinical need to monitor such therapies on an individual basis Traditional platelet tests including light transmission aggregometry (LTA) are inconvenient for acute diagnostic testing. Hence, the introduction of "near-patient" test systems
Here we describe the utility of a point ofcare (POC) test platform (PlateletWorks ® ) for monitoring platelet response to ADP and arachidonic acid (AA) as the agonists
Methods & Procedure:
PlateletWorks (Helena Laboratories, Beaumont, TX) evaluates nonanticoagulated whole blood as the sample medium. It utilizes the principle of differential platelet counting in either the absence or presence of a platelet agonist (ADP, collagen, AA etc.) as a direct indication of platelet function. Results may be expressed as either % aggregation or % inhibition.
In human clinical trials subjects (n=205) were evaluated for their response to ADP (20μM) and a second group of subjects (n=40) were evaluated for their response to AA (either 5μM or 1.25mg) on both the Plateletworks and LTA (Chronolog, Haverstown, PA) test platforms.
Results:
The comparative data for each agonist between the two platforms are shown in Figures 1 & 2 
